June 29th, 2022

Podcast 294: PD-1 blockade in locally advanced rectal cancer

Locally advanced rectal cancer usually receives a three-part treatment: chemotherapy followed by radiotherapy and then surgery.

In a small-cohort study presented at this year’s ASCO conference researchers used a PD-1 inhibitor — dostarlimab — every three weeks for 6 months against the disease. All patients had mismatch repair deficient tumors. No other treatments were needed however, since the 12 patients all attained complete response if they completed the regimen.

As part of the NEJM Group’s coverage of ASCO, Christine Sadlowski interviewed the study’s first author, Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Centern about the study and its implications.

The study as published in the New England Journal of Medicine

Leave a Reply

Your email address will not be published.

Note: This is a moderated forum. By clicking on the "Submit Comment" button below, you agree to abide by the NEJM Journal Watch Terms of Use.

Our physician bloggers cannot respond to requests for personal medical advice, and recommend patients discuss health issues with their individual physicians.

Clinical Conversations

About the Podcast

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.

Follow us:
Follow on Apple Podcasts

Follow on Google Podcasts